Abstract
New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 465-469 |
| Number of pages | 5 |
| Journal | Autoimmunity Reviews |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Apr 2010 |
Fingerprint
Keywords
- Anti-TNF-alpha
- DMARDs
- Methotrexate
- Rheumatoid arthritis
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
Cite this
Switching TNF-alpha antagonists in rheumatoid arthritis : The experience of the LORHEN registry. / Caporali, Roberto; Sarzi-Puttini, Piercarlo; Atzeni, Fabiola; Gorla, Roberto; Filippini, Matteo; Marchesoni, Antonio; Favalli, Ennio Giulio; Bobbio-Pallavicini, Francesca; Montecucco, Carlomaurizio.
In: Autoimmunity Reviews, Vol. 9, No. 6, 04.2010, p. 465-469.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Switching TNF-alpha antagonists in rheumatoid arthritis
T2 - The experience of the LORHEN registry
AU - Caporali, Roberto
AU - Sarzi-Puttini, Piercarlo
AU - Atzeni, Fabiola
AU - Gorla, Roberto
AU - Filippini, Matteo
AU - Marchesoni, Antonio
AU - Favalli, Ennio Giulio
AU - Bobbio-Pallavicini, Francesca
AU - Montecucco, Carlomaurizio
PY - 2010/4
Y1 - 2010/4
N2 - New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.
AB - New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.
KW - Anti-TNF-alpha
KW - DMARDs
KW - Methotrexate
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=77950300568&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950300568&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2009.12.010
DO - 10.1016/j.autrev.2009.12.010
M3 - Article
C2 - 20044040
AN - SCOPUS:77950300568
VL - 9
SP - 465
EP - 469
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 6
ER -